Transcriptional control of viral gene therapy by cisplatin
James O. Park, … , Donald W. Kufe, Ralph R. Weichselbaum
James O. Park, … , Donald W. Kufe, Ralph R. Weichselbaum
Published August 1, 2002
Citation Information: J Clin Invest. 2002;110(3):403-410. https://doi.org/10.1172/JCI15548.
View: Text | PDF
Article Genetics

Transcriptional control of viral gene therapy by cisplatin

Abstract

Research Article

Authors

James O. Park, Carlos A. Lopez, Vinay K. Gupta, Charles K. Brown, Helena J. Mauceri, Thomas E. Darga, Abdullah Manan, Samuel Hellman, Mitchell C. Posner, Donald W. Kufe, Ralph R. Weichselbaum

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
In vivo regrowth studies. The effect of combined treatment with Ad.Egr.T...
In vivo regrowth studies. The effect of combined treatment with Ad.Egr.TNF.11D and cisplatin was evaluated by measuring the volume of xenografts injected with Ad.Null.3511.11D or Ad.Egr.TNF.11D with or without cisplatin. Day 0 represents the first day of treatment. (a) In Seg-1 xenografts, combined treatment with Ad.Egr.TNF.11D and cisplatin produced significant tumor regression compared with tumors treated with Ad.Null.3511.11D and cisplatin on days 4 (P = 0.045), 6 (P < 0.005), 8 (P < 0.002), 10 (P < 0.001), 12 (P < 0.004), and 14 (P < 0.021). (b) In PROb xenografts, significant tumor regression was observed in the tumors receiving combined treatment with Ad.Egr.TNF.11D and cisplatin compared with tumors treated with Ad.Null.3511.11D and cisplatin on days 4 (P = 0.045), 6 (P < 0.001), 8 (P = 0.048), 10 (P < 0.001), 12 (P < 0.001), and 14 (P = 0.002). Data are reported as mean ± SEM.